June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Effect of Prostaglandin Analog Type in a Study Comparing the Additive Effect of Brinzolamide 1%/Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension Treated with a Prostaglandin Analog
Author Affiliations & Notes
  • Jonathan S Myers
    Glaucoma, Wills Eye Hospital, Philadelphia, PA
  • Harvey Dubiner
    Clayton Eye Center, Morrow, GA
  • Donald L Budenz
    Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, NC, NC
  • Douglas Hubatsch
    Alcon Laboratories, Inc., Fort Worth, TX
  • Robert Fechtner
    Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers, Newark, NJ
  • Footnotes
    Commercial Relationships Jonathan Myers, Alcon labs (F); Harvey Dubiner, Alcon (R); Donald Budenz, None; Douglas Hubatsch, Alcon (E); Robert Fechtner, Alcon (C), Santen (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5808. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jonathan S Myers, Harvey Dubiner, Donald L Budenz, Douglas Hubatsch, Robert Fechtner; Effect of Prostaglandin Analog Type in a Study Comparing the Additive Effect of Brinzolamide 1%/Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension Treated with a Prostaglandin Analog. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5808.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC) has been evaluated as an adjunct to prostaglandin analog (PGA) therapy in a 6-week study, and has proven efficacious in producing further IOP lowering in this recently completed study.1 Here, we report results of an analysis done to determine differences in IOP-lowering efficacy of BBFC when added to TRAVATAN Z®, XALATAN® or LUMIGAN® monotherapy.<br /> 1 Accepted for presentation at the 2015 Annual Meeting of the American Glaucoma Society

 
Methods
 

NCT01937312 is a 2-arm, phase 4, randomized, double-masked study, which evaluated the additive effect of BBFC in patients on PGA monotherapy (TRAVATAN Z®, XALATAN® and LUMIGAN®). The primary efficacy endpoint was mean diurnal IOP at 6 weeks; which was the measure used to compare the effect of the individual PGAs on IOP-lowering in combination with BBFC. Descriptive statistics were provided.

 
Results
 

In the full ITT cohort, the mean diurnal IOP at 6 weeks was 17.1 mmHg (±0.4 SE) in the BBFC+PGA group (n=88) and 20.5 mmHg (±0.4 SE) in the Vehicle + PGA group (n=94). When analyzed by PGA-monotherapy subgroups, the mean diurnal IOP in the BBFC+PGA and Vehicle + PGA groups respectively was 17.45 mmHg (±0.53 SE; n=23) vs 20.40 mmHg (±0.69 SE; n=23) for TRAVATAN Z®; 16.78 mmHg (±0.50 SE; n=31) vs 19.99 mmHg (±0.69 SE; n=37) for XALATAN® and 16.9 mmHg (±0.62 SE; n=29) vs 20.78 mmHg (±0.71 SE; n=32) for LUMIGAN® (Figure 1).

 
Conclusions
 

The additive effect of BBFC in lowering mean diurnal IOP, when added to PGA monotherapy was maintained at levels similar to the full cohort, when analyzed by type of PGA (TRAVATAN Z®, XALATAN® or LUMIGAN®) used.  

 
Figure 1. Additive effect of BBFC and PGA-type on mean diurnal IOP (±SE)
 
Figure 1. Additive effect of BBFC and PGA-type on mean diurnal IOP (±SE)

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×